Literature DB >> 12185218

Acid suppression in gastro-oesophageal reflux disease: Why? How? How much and when?

M P Jones1.   

Abstract

For patients with suboptimal relief from lifestyle modifications, acid suppressive therapy remains a cornerstone of treatment for gastro-oesophageal reflux disease (GORD). While a great deal of attention is focused on complications of GORD, adequate symptom relief remains an important and practical therapeutic goal. Adequate symptom relief is an achievable and easily measurable endpoint that both restores quality of life and prevents many potential complications.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12185218      PMCID： PMC1742452          DOI： 10.1136/pmj.78.922.465

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  19 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

2.  Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.

Authors:  C W Howden; J M Henning; B Huang; N Lukasik; J W Freston
Journal:  Am J Gastroenterol       Date:  2001-06       Impact factor: 10.864

3.  Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.

Authors:  A S Mee; J L Rowley
Journal:  Aliment Pharmacol Ther       Date:  1996-10       Impact factor: 8.171

4.  Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life.

Authors:  N I McDougall; B T Johnston; F Kee; J S Collins; R J McFarland; A H Love
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

5.  Omeprazole therapy decreases the need for dilatation of peptic oesophageal strictures.

Authors:  G O Barbezat; M Schlup; R Lubcke
Journal:  Aliment Pharmacol Ther       Date:  1999-08       Impact factor: 8.171

6.  Methodological aspects of evaluation of Quality of Life in upper gastrointestinal diseases.

Authors:  E Dimenäs
Journal:  Scand J Gastroenterol Suppl       Date:  1993

7.  Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial.

Authors:  J G Hatlebakk; A Berstad; L Carling; L E Svedberg; P Unge; P Ekström; L Halvorsen; A Stallemo; N Hovdenak; R Trondstad
Journal:  Scand J Gastroenterol       Date:  1993-03       Impact factor: 2.423

Review 8.  Review article: drug therapy for reflux oesophagitis.

Authors:  W A de Boer; G N Tytgat
Journal:  Aliment Pharmacol Ther       Date:  1994-04       Impact factor: 8.171

9.  Empiric therapy for gastroesophageal reflux disease.

Authors:  N E Schindlbeck; A G Klauser; W A Voderholzer; S A Müller-Lissner
Journal:  Arch Intern Med       Date:  1995-09-11

10.  Quality of Life assessments in the evaluation of gastroesophageal reflux and peptic ulcer disease before, during and after treatment.

Authors:  H Glise; B Hallerbäck; B Johansson
Journal:  Scand J Gastroenterol Suppl       Date:  1995
View more
  3 in total

Review 1.  Treatment of uncomplicated reflux disease.

Authors:  Joachim Labenz; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  2005-07-28       Impact factor: 5.742

Review 2.  Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.

Authors:  Katsuhiko Iwakiri; Yoshikazu Kinoshita; Yasuki Habu; Tadayuki Oshima; Noriaki Manabe; Yasuhiro Fujiwara; Akihito Nagahara; Osamu Kawamura; Ryuichi Iwakiri; Soji Ozawa; Kiyoshi Ashida; Shuichi Ohara; Hideyuki Kashiwagi; Kyoichi Adachi; Kazuhide Higuchi; Hiroto Miwa; Kazuma Fujimoto; Motoyasu Kusano; Yoshio Hoshihara; Tatsuyuki Kawano; Ken Haruma; Michio Hongo; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-06-21       Impact factor: 7.527

3.  Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.

Authors:  Yoshikazu Kinoshita; Mototsugu Kato; Mitsuhiro Fujishiro; Hironori Masuyama; Ryo Nakata; Hisanori Abe; Shinji Kumagai; Yasushi Fukushima; Yoshiumi Okubo; Seiichiro Hojo; Motoyasu Kusano
Journal:  J Gastroenterol       Date:  2017-11-29       Impact factor: 7.527
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.